
## Miyoung Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6555668/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD). Journal of Allergy and Clinical Immunology, 2022, 149, 1340-1347.e4.	2.9	32
2	Photo-Protective Effect of AP Collagen Peptides on UV-Induced Skin Aging. Journal of the Korean Society of Food Science and Nutrition, 2021, 50, 119-127.	0.9	4
3	A TRPV1 antagonist, PAC-14028 does not increase the risk of tumorigenesis in chemically induced mouse skin carcinogenesis. Regulatory Toxicology and Pharmacology, 2020, 112, 104613.	2.7	6
4	Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment. Cell Biology and Toxicology, 2018, 34, 143-162.	5.3	14
5	A novel, topical, nonsteroidal, TRPV1 antagonist, PAC-14028 cream improves skin barrier function and exerts anti-inflammatory action through modulating epidermal differentiation markers and suppressing Th2 cytokines in atopic dermatitis. Journal of Dermatological Science, 2018, 91, 184-194.	1.9	28